YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* NeOnc Technologies (NTHI [https://seekingalpha.com/symbol/NTHI]) said [https://seekingalpha.com/pr/20655074-neonc-technologies-redeems-all-outstanding-series-a-convertible-preferred-stock-and] on Thursday that it had redeemed all 6,000 o…
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. Clea…
DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics(NASDAQ: ERNA), and VivoSim Labs(NASDAQ: VIVS) highlight three distinct pathways to potential…
DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemo…
DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that…
DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical dev…
(RTTNews) - Tuesday's top gainers include CervoMed, with key clinical trial catalysts ahead; Conexeu, which strengthened its leadership with board expansion; NeOnc, advancing its lead drug candidate into Phase 2 for aggressive brain tumour…
DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple clinical programs targeting some of the…
With a stock price of $4.64, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) is among the 8 Best Up and Coming Penny Stocks to Buy Now. On May 19, Alliance Global initiated coverage of NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) with a…
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most importan…
DENVER, May 27, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across…
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing atte…
Quick Read NeOnc and Plus Therapeutics operate in the same CNS oncology space as CNS Pharmaceuticals but carry deeper pipelines, real funding, and commercial traction that can deliver near-term catalysts without the cash constraints and bi…
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stake…
CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today annou…
CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancer…
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOncTechnologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant b…
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for…
NeOnc Technologies Holdings, Inc.image1.jpeg CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering ther…
NeOnc Technologies Holdings, Inc. CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for…
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cance…
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (Nasdaq: BGL) ("Blue Gold" or the “Company”), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner and…
CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CN…
CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the c…
* NeOnc Technologies Holdings press release [https://seekingalpha.com/pr/20205072-neonc-technologies-holdings-reports-second-quarter-2025-results-and-provides-operational] (NASDAQ:NTHI [https://seekingalpha.com/symbol/NTHI]): Q2 GAAP EPS o…
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a small-cap biotech company with a market capitalization of $97.42 million, announced Monday that its unaudited consolidated financial statements for the quarter ended March 31, 2025, should…
ABU DHABI - NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), currently valued at $91.14 million, announced Monday that its subsidiary NuroMENA Holdings Ltd. has been officially incorporated by the Abu Dhabi Global Market (ADGM), fulfilling…
CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, to…
CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signin…
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/profile] 23.45…
* NeOnc Technologies (NASDAQ:NTHI [https://seekingalpha.com/symbol/NTHI]) said on Tuesday that it has signed a definitive agreement [https://seekingalpha.com/pr/20181029-neonc-technologies-signs-definitive-agreement-for-50-million-strategi…
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced…
* NeOnc Technologies (NASDAQ:NTHI [https://seekingalpha.com/symbol/NTHI]) filed a prospectus to resale 10.02M shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder.…
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug d…
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development…
-- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for centra…